FMP

FMP

Enter

NTLA - Intellia Therapeutic...

Financial Summary of Intellia Therapeutics, Inc.(NTLA), Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. T

photo-url-https://financialmodelingprep.com/image-stock/NTLA.png

Intellia Therapeutics, Inc.

NTLA

NASDAQ

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

24.84 USD

-0.04 (-0.161%)

About

ceo

Dr. John M. Leonard M.D.

sector

Healthcare

industry

Biotechnology

website

https://www.intelliatx.com

exchange

NASDAQ

Description

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Reg...

CIK

0001652130

ISIN

US45826J1051

CUSIP

45826J105

Address

40 Erie Street

Phone

857 285 6200

Country

US

Employee

526

IPO Date

May 6, 2016

Summary

CIK

0001652130

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

45826J105

ISIN

US45826J1051

Country

US

Price

24.84

Beta

1.85

Volume Avg.

1.41M

Market Cap

2.4B

Shares

-

52-Week

19.37-47.48

DCF

-4.64

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-4.63

P/B

-

Website

https://www.intelliatx.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest NTLA News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep